Faith Haines Kolb Joins PROMETRIKA as Senior Director of Clinical Operations and Data ...( Move further expands PROMETRIKA's fo...)

Move further expands PROMETRIKA's focus in key areas in contract research including clinical trial planning and execution, clinical monitoring, and

data management/electronic data capture.

CAMBRIDGE, Mass., June 17 /PRNewswire/ -- PROMETRIKA, LLC, a contract research organization providing a full range of clinical research services for clients in pharmaceuticals, biologics and medical devices, today announced that Faith Haines Kolb has joined the company as senior director of clinical operations and data management. With more than 19 years of experience in clinical research, Ms. Kolb has set up and managed multiple large scale clinical research programs from planning through all phases of execution, data management, and reporting.

"Faith Haines Kolb is one of the most experienced clinical research professionals working in the field today. As we continue to expand our services in the clinical research areas that are critical for our clients at PROMETRIKA, her demonstrated strengths in project management, monitoring, electronic data capture, and working successfully with global research networks will be a tremendous asset for us moving forward," said Miganush Stepanians, PhD, president and CEO of PROMETRIKA.

Prior to joining PROMETRIKA, Ms. Kolb was chief technical officer at Averion International Corporation, an international clinical research organization. At Averion she was responsible for the company's operational performance in the United States. Prior to joining Averion, she was director of clinical IT at PAREXEL International Corporation.

"In my work I have seen the many challenges in pharmaceutical product development facing companies in the U.S. and around the world. With a strong focus on improving clinical research services for pharmaceutical, biotechnology and medical device companies, PROMETRIKA is setting a new standard in terms of efficiency and quality control for clinical trials. I am very pleased t
'/>"/>